• About
  • Masthead
  • License Content
  • Advertise
  • Submit Press Release
  • RSS/Email List
  • Write for us
  • Contact us
2 Minute Medicine
No Result
View All Result

No products in the cart.

SUBSCRIBE
  • Specialties
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • Wellness
  • Classics™
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Visual
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • AccountLog-in/out
    • Subscribe
    • Sign-in
    • My account
2 Minute Medicine
  • Specialties
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • Wellness
  • Classics™
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Visual
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • AccountLog-in/out
    • Subscribe
    • Sign-in
    • My account
SUBSCRIBE
2 Minute Medicine
Subscribe
Home All Specialties Cardiology

Wearable cardioverter-defibrillators do not reduce mortality within 90 days of myocardial infarction

byDayton McMillan
October 4, 2018
in Cardiology, Chronic Disease
Reading Time: 3 mins read
0
Share on FacebookShare on Twitter

1. Patients with an acute myocardial infarction (MI) and ejection fraction less than 35% did not have reduced incidence of arrhythmic death within 90 days of the index MI compared to control patients.

2. Incidence of nonarrythmic death was also similar within 90 days of MI for patients in the device and control groups.

Evidence Rating Level: 1 (Excellent)     

Study Rundown: Incidence of sudden cardiac death is elevated in the period following a MI. Implantable cardioverter-defibrillators (ICDs) have shown mortality benefits when implanted months after MI, but no mortality benefit has been shown for ICDs implanted acutely following MI. In this high-risk period wearable cardioverter-defibrillators may provide mortality benefit to patients before they undergo an ICD procedure. The Vest Prevention of Early Sudden Death Trial (VEST) assessed the efficacy of wearable cardioverter-defibrillators in patients up to 90 days post MI. The primary outcome of composite arrhythmic death at 90 days post-MI was not significantly different between the wearable device group and a control group. Rates of nonarrythmic death also did not differ between the groups, while death due to any cause was lower in the device group.

Strengths of this study include its randomized design, multinational patient recruitment, and training of patients on appropriate device use. Limitations include possible study underpowering for detection of the all-cause mortality outcome and difficulties in delineating arrhythmic from nonarrythmic causes of death.

Click to read the study in NEJM

Relevant Reading: Aggregate national experience with the wearable cardioverter-defibrillator: event rates, compliance, and survival

RELATED REPORTS

Mediterranean diet superior to low-fat diet in secondary prevention of cardiovascular events

Improved mortality rates for myocardial infarction, stroke, and pulmonary embolism in patients receiving dialysis between 1998 to 2015

Ophthalmologic procedures are not associated with increased risk for acute myocardial infarction

In-Depth [randomized controlled trial]: This multicenter, randomized controlled trial recruited patients between 2008 and 2017. Eligible patients were hospitalized for an acute MI and had an ejection fraction of 35% or less. Patients were enrolled in the study within 7 days of discharge. Exclusion criteria included having an ICD, were undergoing hemodialysis, or had a chest wall to small or large to accommodate the device. Randomization occurred in a 2:1 fashion, with patients in device (n=1524) or control (n=778) groups. Patients with the device were to wear it at all times for 3 months except when bathing. Follow-up occurred at 1 and 3 months. Median ejection fraction was 28%, and percutaneous coronary intervention during hospitalization occurred in 83.6% of patients. Patients in the device group wore the device for a median of 18 hours per day and for a mean of 14 hours per day. Mean follow-up was 84.3 days. Rates of arrhythmic death at 90 days were 1.6% in the device group and 2.4% in the control group (relative risk [RR], 0.67; 95% confidence interval [CI], 0.37 to 1.21; P=0.18). Death from all causes was 3.1% in the device group and 4.9% in the control group (RR, 0.64; 95% CI, 0.43 to 0.98; uncorrected P=0.04). Nonarrythmic death occurred in 1.4% of the device group and 2.2% of the control group (RR, 0.63; 95% CI, 0.33 to 1.19; uncorrected P=0.15). For patients wearing the devices, the average rate of alarms for possible arrhythmias was 0.033 alarms per hour. A shock was received by 29 patients in the device group, with 20 deemed appropriate and 9 deemed inappropriate shocks.  Symptomatically, more patients in the device group reported itching and rash while fewer patients in the device group reported shortness of breath, as compared to the control group.

Image: PD

©2018 2 Minute Medicine, Inc. All rights reserved. No works may be reproduced without expressed written consent from 2 Minute Medicine, Inc. Inquire about licensing here. No article should be construed as medical advice and is not intended as such by the authors or by 2 Minute Medicine, Inc.

Tags: myocardial infarction
Previous Post

Superwarfarin contaminants found in synthetic cannabinoid-associated coagulopathy outbreak

Next Post

Physical therapy noninferior to arthroscopic partial meniscectomy for partial nonobstructive meniscal tears

RelatedReports

FDA-approved weight loss medications associated with weight loss at one year
Cardiology

Mediterranean diet superior to low-fat diet in secondary prevention of cardiovascular events

May 25, 2022
Fish oil and aspirin did not reduce arteriovenous fistula failure: The FAVOURED trail
Cardiology

Improved mortality rates for myocardial infarction, stroke, and pulmonary embolism in patients receiving dialysis between 1998 to 2015

April 22, 2022
Nonpowder gun-related pediatric eye injuries on the rise
Cardiology

Ophthalmologic procedures are not associated with increased risk for acute myocardial infarction

April 22, 2022
30-Day mortality decreased in UK pediatric cardiac surgery from 2000-2010
Cardiology

Clinically important troponin I threshold for mortality after cardiac surgery

March 8, 2022
Next Post
Recent surgery, operative times increase complications of knee arthroscopy

Physical therapy noninferior to arthroscopic partial meniscectomy for partial nonobstructive meniscal tears

Computed tomography improves diagnostic certainty in the emergency department

Acetaminophen reduces recurrence of febrile seizures in children within same fever episode

Blood type correlates with egg reserve in infertile women

Continuous or extended combined oral contraceptive regimens not linked to higher venous thromboembolism risk

License Our Award-Winning Physician-Written Medical News and Visual Abstracts

2 Minute Medicine is the leading authoritative medical news licensing service, and the only with reports written by practicing doctors.

LICENSE CONTENT

Get 2MM+ Premium Access

No ads & unlimited access to all current reports, over 9000 searchable archived reports, visual abstracts, Weekly Rewinds, and the online edition of The Classics Series™ textbook.

Subscription Options
2 Minute Medicine

2 Minute Medicine® is an award winning, physician-run, expert medical media company. Our content is curated, written and edited by practicing health professionals who have clinical and scientific expertise in their field of reporting. Our editorial management team is comprised of highly-trained MD physicians. Join numerous brands, companies, and hospitals who trust our licensed content.

Recent Reports

  • #VisualAbstract: Bimekizumab shows a favourable 2-year safety profile in patients with moderate to severe plaque psoriasis
  • Medical cannabis provides little improvement to sleep in chronic pain patients
  • Alzheimer disease in individuals with Down syndrome has similar variability in age of onset and mortality rate as autosomal dominant forms
License Content
Terms of Use | Disclaimer
Cookie Policy
Privacy Statement (EU)
Disclaimer

© 2021 2 Minute Medicine, Inc. - Physician-written medical news.

  • Specialties
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • Wellness
  • Classics™
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Visual
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • Account
    • Subscribe
    • Sign-in
    • My account

© 2021 2 Minute Medicine, Inc. - Physician-written medical news.